New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
06:32 EDTLLYEli Lilly, Kowa says LIVALO 4 mg study met primary endpoint
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a study evaluating the efficacy of LIVALO 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholestero in HIV-infected adults with high cholesterol, or dyslipidemia. The study was designed as a superiority trial for the primary endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with dyslipidemia; with and without viral Hepatitis B or C. The study met its primary endpoint. Results showed that, after 12 weeks of therapy, pitavastatin had a significantly greater decrease in LDL-C compared with pravastatin. The results were presented yesterday at a late-breaking poster presentation at the 20th Conference on Retroviruses & Opportunistic Infections in Atlanta, GA.
News For LLY From The Last 14 Days
Check below for free stories on LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTLLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 11, 2014
11:58 EDTLLYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use